Functional and Predictive Assays for Biotherapeutics Development

Many biotherapeutic developers use the services of ReachBio Research Labs as an important part of their biologic development programs. Take advantage of our experience, flexibility and research depth to tailor assays to suit your needs. Our experience supporting biotherapeutic development includes assays to evaluate primary cell functionality and toxicity of monoclonal antibodies, bi-specific antibodies, antibody-drug conjugates, nanobodies and other biologics.

Examples of our Assays Supporting Biotherapeutics Development

Blood & Bone Marrow Toxicity Assays
Evaluate and rank your biotherapeutic candidates for their risk of clinical thrombocytopenia, neutropenia or severe anemia

Correlation of in vitro CFC IC50 values with clinical neutropenia

Image 17








Learn More


Cancer Stem Cell Assays
Evaluate and rank the effectiveness of your biotherapeutic candidates at inhibiting expansion of cancer stem cells and cancer progenitor cells
  • Applicable to both biologics and small molecules
  • Measure functional inhibition of cancer progenitor cell expansion
  • Evaluate therapies that target cell surface receptors (e.g. CD24) and stem cell-associated signaling pathways (e.g. Wnt/Hedgehog)
  • Customized to your program’s needs

Learn More


Cancer Immunotherapy & ADCC Assays
Evaluate and rank the ability of your candidates to recruit T cells and NK cells to kill cancer cells
  • In vitro antibody-dependent cellular cytotoxicity ADCC assays
  • Compatible with bi-specific antibodies and other immune cell recruiters
  • Measure primary immune cell killing of target cells
  • Flow cytometry-based readout with additional intracellular analysis, if desired
  • Customized to your program’s needs


Cytokine Storm & Cytokine Release Syndrome Assays
Evaluate and rank the potential risk of your candidates to induce cytokine release or cytokine storms with our predictive in vitro assays
  • Human primary cell-based assays* with pro-inflammatory cytokine quantification using the Luminex platform
  • Uses the soluble, not plastic-immobilized form of the biologic, allowing for more biological relevance and more precise dose-response curves
  • Helps to understand the risk of non-specific immune cell activation prior to NHP studies

*Human cells are more relevant at predicting risk of cytokine storms or cytokine release syndrome than are in vivo primate models due to nuanced immunological differences between the species.


Download our BIOTHERAPEUTICS DEVELOPMENT SUPPORT Brochure for additional information.


Please CONTACT US to be put in direct contact with a senior scientist to discuss your project’s needs.